Technical Analysis for OTLK - Outlook Therapeutics, Inc.

Grade Last Price % Change Price Change
C 2.19 -2.67% -0.06
OTLK closed down 2.67 percent on Friday, April 9, 2021, on 10 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical OTLK trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish -2.67%
Bollinger Band Squeeze Range Contraction -2.67%
20 DMA Resistance Bearish -2.23%
Bollinger Band Squeeze Range Contraction -2.23%
BB Squeeze Started Range Contraction -2.23%
Fell Below 20 DMA Bearish -0.90%
Older End-of-Day Signals for OTLK ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 2 days ago
Down 3% 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago
Fell Below 10 DMA 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Outlook Therapeutics, Inc. Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Antibodies Monoclonal Antibody Monoclonal Antibodies Cancer Treatments Ophthalmic Macular Degeneration Related Macular Degeneration Specialty Drugs Retina Wet Age Related Macular Degeneration Age Related Macular Degeneration

Is OTLK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.26
52 Week Low 0.58
Average Volume 5,581,259
200-Day Moving Average 1.37
50-Day Moving Average 2.17
20-Day Moving Average 2.27
10-Day Moving Average 2.21
Average True Range 0.19
ADX 14.73
+DI 20.44
-DI 21.80
Chandelier Exit (Long, 3 ATRs ) 1.96
Chandelier Exit (Short, 3 ATRs ) 2.48
Upper Bollinger Band 2.46
Lower Bollinger Band 2.08
Percent B (%b) 0.28
BandWidth 16.76
MACD Line 0.02
MACD Signal Line 0.04
MACD Histogram -0.0168
Fundamentals Value
Market Cap 278.53 Million
Num Shares 127 Million
EPS -2.89
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 10.08
Price-to-Book 13.92
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.30
Resistance 3 (R3) 2.30 2.28 2.28
Resistance 2 (R2) 2.28 2.25 2.27 2.27
Resistance 1 (R1) 2.23 2.23 2.22 2.23 2.27
Pivot Point 2.21 2.21 2.20 2.20 2.21
Support 1 (S1) 2.16 2.18 2.15 2.16 2.11
Support 2 (S2) 2.14 2.16 2.13 2.11
Support 3 (S3) 2.09 2.14 2.10
Support 4 (S4) 2.09